Suppliers and packagers for generic pharmaceutical drug: Eteplirsen

Eteplirsen

Listed suppliers include manufacturers, repackagers, relabelers, and private labeling entitities.

Applicant	Tradename	Generic Name	Dosage	NDA	NDA/ANDA	Supplier	Package Code	Package	Marketing Start
Sarepta Theraps Inc	EXONDYS 51	eteplirsen	SOLUTION;INTRAVENOUS	206488	NDA	Sarepta Therapeutics, Inc.	60923-284-10	1 VIAL, SINGLE-USE in 1 CARTON (60923-284-10) / 10 mL in 1 VIAL, SINGLE-USE	2016-09-19
Sarepta Theraps Inc	EXONDYS 51	eteplirsen	SOLUTION;INTRAVENOUS	206488	NDA	Sarepta Therapeutics, Inc.	60923-363-02	1 VIAL, SINGLE-USE in 1 CARTON (60923-363-02) / 2 mL in 1 VIAL, SINGLE-USE	2016-09-19

Eteplirsen suppliers and manufacturing sources for Exondys 51 (eteplirsen)

Last updated: May 25, 2026

Executive summary: Eteplirsen (Exondys 51) is supplied for FDA commercial distribution through a limited number of qualified biologics manufacturing and fill-finish nodes. The product is produced as a sterile drug substance and drug product (single-use vials) under biologics GMP controls, with supply continuity tied to the manufacturing sites supporting Sarepta’s regulatory filings and quality systems. Public information most reliably identifies Sarepta Therapeutics as the marketing authorization holder and points to contract manufacturing/fill-finish and release testing suppliers named in FDA chemistry, manufacturing, and controls (CMC) submissions and inspection records.

Who are the suppliers for eteplirsen (Exondys 51) and who manufactures it?

Direct answer: Sarepta Therapeutics is the listed applicant/label holder for eteplirsen (Exondys 51) in the US. The “supplier” footprint for eteplirsen in practice is split between:

• Drug substance manufacturing (upstream biologics production, purification).
• Drug product manufacturing (formulation, aseptic fill-finish, labeling, packaging).
• Quality and release testing (site-level analytics and batch release).
• Logistics and distribution (commercial distribution chain).

Key roles, by public regulatory pattern

• Marketing authorization holder: Sarepta Therapeutics, Inc.
• Manufacturing and release are performed at named GMP sites supporting the NDA biologics CMC section and validated during site inspections.

Which manufacturing sites support eteplirsen GMP supply?

Publicly indexed supplier identifiers for biologics are typically anchored to:

• FDA inspectional facility names and addresses tied to sterile manufacturing and biologics CMC.
• The manufacturing site language in the NDA biologics license application CMC and annual product quality reporting.
• Label sections that identify the manufacturer/distributor where applicable.

For eteplirsen, the most decision-useful “supplier list” is the set of GMP sites shown on FDA-reviewed CMC/manufacturing descriptions tied to commercial batches.

What FDA approvals and labeling indicate who supplies Exondys 51?

Direct answer: FDA labeling and FDA administrative/CMC listings indicate Sarepta as the drug labeler/holder and identify manufacturing/distribution information by site where that information is included on the US package labeling and FDA databases.

Orange Book status and how it affects supplier visibility

Eteplirsen is a biologic and is generally not listed in the US FDA Orange Book (which is oriented to small-molecule drug approvals and patents). That means the most direct supplier visibility comes from:

• FDA biologics licensing application and CMC content
• FDA inspection history
• FDA product labeling and distribution information

How is eteplirsen manufactured (drug substance vs drug product) and who are the typical suppliers by node?

Direct answer: Eteplirsen manufacturing is not like a small-molecule API supply chain. It is a sterile biologics process with controlled aseptic fill-finish. Supplier roles typically map to these nodes.

Drug substance supplier role

• Synthesis and purification under GMP
• Characterization and release of intermediates and bulk drug substance

Drug product supplier role

• Formulation buffer and stability-controlled process
• Aseptic fill-finish into single-use vials
• Sterility assurance, particulates testing, and finished product release

Quality-release supplier role

• Analytical testing (identity, purity, potency, sterility where applicable)
• Batch disposition at or under GMP release frameworks

Distribution supplier role

• Cold chain logistics compatible with the product’s storage conditions

Which contract manufacturing organizations are involved in eteplirsen supply?

Direct answer: Contract manufacturing organizations for eteplirsen supply are identified through the specific manufacturing site(s) listed in Sarepta’s filed CMC and FDA inspection records. For a reliable supplier list, the only defensible approach is to tie each supplier to a named facility shown in FDA sources for the NDA biologics manufacturing.

Business implication: supplier risk for eteplirsen is primarily a facility risk (sterile manufacturing capacity, aseptic suite availability, QC release capacity), not a commodity supply risk.

What bottlenecks create supplier risk for eteplirsen (Exondys 51)?

Direct answer: The dominant supplier risks are tied to:

• Aseptic fill-finish capacity for sterile biologics
• Analytical testing capacity for batch release
• Regulatory quality systems and inspection outcomes
• Batch schedule dependencies between drug substance and drug product nodes

Facility and quality system drivers

• Sterile manufacturing suite uptime and HEPA/utility qualification
• Raw material qualification for drug substance process inputs
• Stability and container closure requirements for single-use vial format

How many qualified eteplirsen suppliers exist and can supply be dual-sourced?

Direct answer: For products like eteplirsen, dual-sourcing exists only if Sarepta has filed and validated alternate CMC manufacturing routes and suppliers in regulatory dossiers. If not, supply remains single-threaded to one qualified GMP chain for commercial scale.

Practical supplier mapping

• If multiple GMP sites are listed for manufacturing or fill-finish in FDA records, there is a pathway to multi-sourcing.
• If only one is listed, the supply chain is effectively single-source for that node.

Who supplies eteplirsen for hospitals and specialty pharmacies?

Direct answer: For US distribution, the supply chain typically runs through:

• Direct shipments from the marketing authorization holder’s distribution network
• Specialty pharmacy distribution channels
• Cold-chain logistics providers integrated into the distributor’s approved lanes

Hospital procurement then interfaces through specialty channels rather than standard group purchasing organizations for many orphan and high-cost biologics.

What supplier and regulatory risks matter for generic or biosimilar switching?

Direct answer: Eteplirsen is a targeted oligonucleotide biologic-like therapy. “Generic” switching is not the typical FDA pathway. For supply planning, the key risk is whether any alternate manufacturing route exists for supply continuity rather than whether competitors supply identical products.

Biosimilar switching is less applicable because eteplirsen is not a typical antibody biologic model. Competitor supply, if any, is governed by distinct regulatory pathways and separate CMC and manufacturing qualification.

Commercial exposure: what happens if eteplirsen suppliers face capacity constraints?

Direct answer: Supply interruptions for eteplirsen translate into:

• Missed dosing schedules for patients
• Increased allocation pressure and prioritization
• Potential temporary treatment delays until FDA-labeled batches are released

These impacts are amplified because rare-disease dosing is time-sensitive and patient switching options are limited.

---

Key Takeaways

• Sarepta Therapeutics is the core commercial label holder for eteplirsen (Exondys 51), and supplier identification in practice is tied to named GMP manufacturing and release testing facilities in FDA-reviewed CMC and inspection sources.
• The critical supplier nodes are drug substance, aseptic drug product fill-finish, and QC release capacity.
• Supplier risk for eteplirsen is driven by facility constraints and quality system/CMC batch release timelines, not commodity sourcing.
• A defensible “supplier list” is a facility list grounded in FDA site-specific data tied to the NDA biologics manufacturing chain.

---

FAQs

Is eteplirsen manufactured by Sarepta or by contract manufacturers?

Manufacturing is typically performed at qualified GMP sites tied to Sarepta’s biologics CMC dossier. The practical answer for supply planning is that the drug is produced through Sarepta’s qualified manufacturing network, which can include contract manufacturing nodes depending on the filed CMC.

Where can I find the official manufacturing sites for Exondys 51?

The authoritative sources are FDA biologics CMC/administrative records, facility inspection records, and US label/distribution information where site-specific manufacturer/distributor text is provided.

Does eteplirsen appear in the Orange Book, and does that list suppliers?

Eteplirsen is a biologic and generally does not appear in the Orange Book, so supplier identification is instead anchored in FDA biologics records and labeling/distribution materials.

What supplier failures most commonly disrupt sterile biologics like eteplirsen?

The main drivers are aseptic fill-finish capacity, sterile suite downtime, analytical release bottlenecks, and batch disposition delays tied to QC results.

Can the eteplirsen supply chain be switched to alternate manufacturers quickly?

Only if Sarepta has filed and validated alternate CMC manufacturing routes and sites for commercial release; otherwise, supply is constrained by regulatory qualification and batch release workflows.

---

References (APA)

1. U.S. Food and Drug Administration. (n.d.). FDA biologics product information and labeling for eteplirsen (Exondys 51). https://www.fda.gov/
2. U.S. Food and Drug Administration. (n.d.). FDA inspection and facility information for biologics manufacturing sites (search by manufacturer/facility name associated with Exondys 51/eteplirsen). https://www.fda.gov/
3. Sarepta Therapeutics, Inc. (n.d.). Prescribing information for Exondys 51 (eteplirsen). https://www.accessdata.fda.gov/